Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-01-18
2000-04-11
Berch, Mark L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514248, 544237, 544234, C07D23730, C07D491056, A61K 3150
Patent
active
060488530
ABSTRACT:
Substituted 1-arylphthalazine compositions with the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently
REFERENCES:
patent: 5716956 (1998-02-01), Pelletier
Pelletier, J. Med Chem 39, 344 (1996).
Canon. Chem Abs. 101, 31117 b (1983).
Chen et al., "Evaluation of Five Methods for Testing Anticonvulsant Activities," Proc, Soc. Exp. Biol. Med., 87:334 (1954).
Donevan and Rogawski, "GYKI 52466, a 2,3-Bensodiazepine, Is a Highly Selective, Noncompetitive Antagonist of AMPA/kainate Receptor Responses," Neuron, 10:51-59 (1993).
Hussy and et al., "Functional Properties Of A Cloned 5-hydroxytryptamine Ionotropic Receptor Subunit:Comparison With Native Mouse Receptors," J. Physiol. (Lond.), 481.2:311-323 (1994).
Lipton and Rosenberg, "Excitatory Amino Acids As A Final Common Pathway For Neurologic Disorders," New England Journal of Medicine, 330:613-622 (1994).
McBurney, "Therapeutic Potential of NMDA Antagonists in Neurodegenerative Diseases," Neurobiology of Aging, 15:271-273 (1994).
Meldrum and Smith, "Cerebroprotective Effect of a Non-N-Methyl-D-Aspartate Antagonist, GYKI 52466, After Focal Ischemia in the Rat," Stroke 23:861 (1992).
Meldrum, "Excitatory Amino Acids in Epilepsy and Potential Novel Therapies," Epilepsy Research, 12:189-196 (1992).
Peillet et al., "The non-NMDA antagonists, NBOX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat," Brain Res., 571:115 (1992).
Rogawski et al., "Anticonvulsant Activity of AMPA/kainate antagonists:Comparison of GYKI 52466 and NBOX In Maximal Electroshock and Chemoconvulsant Seizure Models," Epilepsy Research, 15:179-184 (1993).
Tarnawa et al., "Electrophysiological Studies With a 2,3-benzodiazepine Muscle Relaxant:GYKI 52466," Eur. J. Pharmacol., 167:193-199 (1989).
Collins Mark A.
Pelletier Jeffrey C.
Bearsden Bio, Inc.
Berch Mark L.
LandOfFree
1-arylphthalazine antagonists of excitatory amino acid receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1-arylphthalazine antagonists of excitatory amino acid receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1-arylphthalazine antagonists of excitatory amino acid receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1176713